{"protocolSection":{"identificationModule":{"nctId":"NCT00961415","orgStudyIdInfo":{"id":"MO22089"},"secondaryIdInfos":[{"id":"2008-007008-27"}],"organization":{"fullName":"Hoffmann-La Roche","class":"INDUSTRY"},"briefTitle":"AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer","officialTitle":"Open-label Study of Bevacizumab Maintenance Therapy (AVASTIN®) With or Without Pemetrexed After First-line Chemotherapy With Bevacizumab-cisplatin-pemetrexed in Patients With Advanced, Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer (NSCLC)"},"statusModule":{"statusVerifiedDate":"2016-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2009-08"},"primaryCompletionDateStruct":{"date":"2011-05","type":"ACTUAL"},"completionDateStruct":{"date":"2011-05","type":"ACTUAL"},"studyFirstSubmitDate":"2009-08-18","studyFirstSubmitQcDate":"2009-08-18","studyFirstPostDateStruct":{"date":"2009-08-19","type":"ESTIMATED"},"resultsFirstSubmitDate":"2015-11-30","resultsFirstSubmitQcDate":"2016-01-24","resultsFirstPostDateStruct":{"date":"2016-02-22","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-01-24","lastUpdatePostDateStruct":{"date":"2016-02-22","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Hoffmann-La Roche","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This open-label study will assess the efficacy and safety of Avastin with or without pemetrexed as maintenance therapy in patients with advanced, metastatic or recurrent non-small cell lung cancer. In Part 1, patients will receive 4 cycles of treatment with Avastin (7.5mg/kg iv) plus cisplatin (75mg/m2 iv) plus pemetrexed (500mg/m2 iv) on day 1 of each 3-week cycle. In Part 2, patients responding to treatment will be randomized to receive further treatment cycles of Avastin (7.5mg/kg iv every 3 weeks) with or without pemetrexed (500mg/m2 iv every 3 weeks). Anticipated time on study treatment is until disease progression. Target sample size is \\<500 individuals."},"conditionsModule":{"conditions":["Non-Squamous Non-Small Cell Lung Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":376,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Part 1","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]","Drug: cisplatin","Drug: pemetrexed"]},{"label":"Part 2A","type":"EXPERIMENTAL","interventionNames":["Drug: bevacizumab [Avastin]"]},{"label":"Part 2B","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: bevacizumab [Avastin]","Drug: pemetrexed"]}],"interventions":[{"type":"DRUG","name":"bevacizumab [Avastin]","description":"7.5mg/kg iv on day 1 of each 3-week cycle","armGroupLabels":["Part 1","Part 2A","Part 2B"]},{"type":"DRUG","name":"cisplatin","description":"75mg/m2 iv on day 1 of each 3-week cycle","armGroupLabels":["Part 1"]},{"type":"DRUG","name":"pemetrexed","description":"500mg/m2 iv on day 1 of each 3-week cycle","armGroupLabels":["Part 1","Part 2B"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Progression Free Survival During Maintenance Treatment Phase","description":"Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","timeFrame":"Up to 21 months"}],"secondaryOutcomes":[{"measure":"Overall Survival During Maintenance Treatment Phase","description":"Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","timeFrame":"Up to 21 months"},{"measure":"Best Overall Response Rate During Maintenance Treatment Phase","description":"The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","timeFrame":"Up to 21 months"},{"measure":"Duration of Response During Maintenance Treatment Phase","description":"Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","timeFrame":"Up to 21 months"},{"measure":"Duration of Disease Control During Maintenance Treatment Phase","description":"Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","timeFrame":"Up to 21 months"},{"measure":"Incidence of Adverse Events and Serious Adverse Event","description":"An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution.","timeFrame":"Up to 21 months"},{"measure":"Number of Participants With Marked Laboratory Abnormalities","description":"Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\\^9/L), for Lymphocytes was 0.70-7.60 (10\\^9/L), and Neutrophil 1.50-9.25 (10\\^9/L ).","timeFrame":"Up to 21 months"},{"measure":"Quality of Life","description":"European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \\[EORTC QLQ-LC13\\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles.","timeFrame":"Up to 21 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adults \\>/=18 years of age\n* inoperable, locally advanced, metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC)\n* at least 1 measurable lesion meeting RECIST criteria\n* ECOG performance status 0-2\n* adequate hematological, liver and renal function\n\nExclusion Criteria:\n\n* prior chemotherapy or treatment with another systemic anti-cancer agent\n* malignancies other than NSCLC within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer or DCIS\n* evidence of tumor invading major blood vessels\n* current or recent use of aspirin (\\>325mg/day) or full-dose anticoagulants or thrombolytic agents for therapeutic purposes\n* history of haemoptysis \\>/=grade 2\n* clinically significant cardiovascular disease","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Clinical Trials","affiliation":"Hoffmann-La Roche","role":"STUDY_DIRECTOR"}],"locations":[{"city":"Béziers","zip":"34500","country":"France","geoPoint":{"lat":43.34122,"lon":3.21402}},{"city":"Bordeaux","zip":"33077","country":"France","geoPoint":{"lat":44.84124,"lon":-0.58046}},{"city":"Bron","zip":"69677","country":"France","geoPoint":{"lat":45.73865,"lon":4.91303}},{"city":"Caen","zip":"14033","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"city":"Caen","zip":"14076","country":"France","geoPoint":{"lat":49.18585,"lon":-0.35912}},{"city":"Clermont-Ferrand","zip":"63003","country":"France","geoPoint":{"lat":45.77969,"lon":3.08682}},{"city":"Créteil","zip":"94010","country":"France","geoPoint":{"lat":48.79266,"lon":2.46569}},{"city":"Gap","zip":"05007","country":"France","geoPoint":{"lat":44.55858,"lon":6.07868}},{"city":"Gleizé","zip":"69400","country":"France","geoPoint":{"lat":45.98916,"lon":4.69708}},{"city":"La Source","zip":"45100","country":"France","geoPoint":{"lat":47.82952,"lon":1.92724}},{"city":"La Tronche","zip":"38700","country":"France","geoPoint":{"lat":45.20507,"lon":5.74629}},{"city":"Lille","zip":"59037","country":"France","geoPoint":{"lat":50.63391,"lon":3.05512}},{"city":"Limoges","zip":"87039","country":"France","geoPoint":{"lat":45.83362,"lon":1.24759}},{"city":"Lyon","zip":"69317","country":"France","geoPoint":{"lat":45.74906,"lon":4.84789}},{"city":"Marseille","zip":"13915","country":"France","geoPoint":{"lat":43.29695,"lon":5.38107}},{"city":"Nancy","zip":"54100","country":"France","geoPoint":{"lat":48.68439,"lon":6.18496}},{"city":"Nîmes","zip":"30900","country":"France","geoPoint":{"lat":43.83665,"lon":4.35788}},{"city":"Paris","zip":"75571","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75674","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Paris","zip":"75970","country":"France","geoPoint":{"lat":48.85341,"lon":2.3488}},{"city":"Perpignan","zip":"66046","country":"France","geoPoint":{"lat":42.69764,"lon":2.89541}},{"city":"Pierre-Bénite","zip":"69495","country":"France","geoPoint":{"lat":45.70359,"lon":4.82424}},{"city":"Reims","zip":"51092","country":"France","geoPoint":{"lat":49.26526,"lon":4.02853}},{"city":"Saint-Priest-en-Jarez","zip":"42770","country":"France","geoPoint":{"lat":45.4739,"lon":4.37678}},{"city":"Strasbourg","zip":"67065","country":"France","geoPoint":{"lat":48.58392,"lon":7.74553}},{"city":"Toulon","zip":"83041","country":"France","geoPoint":{"lat":43.12442,"lon":5.92836}},{"city":"Tours","zip":"37044","country":"France","geoPoint":{"lat":47.39484,"lon":0.70398}},{"city":"Augsburg","zip":"86150","country":"Germany","geoPoint":{"lat":48.37154,"lon":10.89851}},{"city":"Bad Berka","zip":"99437","country":"Germany","geoPoint":{"lat":50.89982,"lon":11.28245}},{"city":"Berlin","zip":"13125","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"city":"Bonn","zip":"53113","country":"Germany","geoPoint":{"lat":50.73438,"lon":7.09549}},{"city":"Ebensfeld","zip":"96250","country":"Germany","geoPoint":{"lat":50.0664,"lon":10.95835}},{"city":"Frankfurt","zip":"60488","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"city":"Freiburg im Breisgau","zip":"79106","country":"Germany","geoPoint":{"lat":47.9959,"lon":7.85222}},{"city":"Gauting","zip":"82131","country":"Germany","geoPoint":{"lat":48.06919,"lon":11.37703}},{"city":"Großhansdorf","zip":"22927","country":"Germany","geoPoint":{"lat":53.66528,"lon":10.28552}},{"city":"Halle","zip":"06120","country":"Germany","geoPoint":{"lat":51.48158,"lon":11.97947}},{"city":"Hamburg","zip":"21075","country":"Germany","geoPoint":{"lat":53.55073,"lon":9.99302}},{"city":"Immenhausen","zip":"34376","country":"Germany","geoPoint":{"lat":51.42763,"lon":9.48017}},{"city":"Karlsruhe","zip":"76137","country":"Germany","geoPoint":{"lat":49.00937,"lon":8.40444}},{"city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"city":"Minden","zip":"32429","country":"Germany","geoPoint":{"lat":52.28953,"lon":8.91455}},{"city":"München","zip":"80336","country":"Germany","geoPoint":{"lat":51.60698,"lon":13.31243}},{"city":"Oldenburg","zip":"26121","country":"Germany","geoPoint":{"lat":53.14118,"lon":8.21467}},{"city":"Alexandroupoli","zip":"68100","country":"Greece","geoPoint":{"lat":40.84995,"lon":25.87644}},{"city":"Lecce","state":"Apulia","zip":"73100","country":"Italy","geoPoint":{"lat":40.35481,"lon":18.17244}},{"city":"Napoli","state":"Campania","zip":"80131","country":"Italy","geoPoint":{"lat":40.87618,"lon":14.5195}},{"city":"Aviano","state":"Friuli Venezia Giulia","zip":"33081","country":"Italy","geoPoint":{"lat":46.07056,"lon":12.59472}},{"city":"Rome","state":"Lazio","zip":"00168","country":"Italy","geoPoint":{"lat":41.89193,"lon":12.51133}},{"city":"Novara","state":"Piedmont","zip":"28100","country":"Italy","geoPoint":{"lat":45.44694,"lon":8.62118}},{"city":"Sassari","state":"Sardinia","zip":"07100","country":"Italy","geoPoint":{"lat":40.72586,"lon":8.55552}},{"city":"Pisa","state":"Tuscany","zip":"56124","country":"Italy","geoPoint":{"lat":43.70853,"lon":10.4036}},{"city":"Padua","state":"Veneto","zip":"35128","country":"Italy","geoPoint":{"lat":45.40797,"lon":11.88586}},{"city":"'s-Hertogenbosch","zip":"5211 RW","country":"Netherlands","geoPoint":{"lat":51.69917,"lon":5.30417}},{"city":"Amersfoort","zip":"3818 ES","country":"Netherlands","geoPoint":{"lat":52.155,"lon":5.3875}},{"city":"Amsterdam","zip":"1066 CX","country":"Netherlands","geoPoint":{"lat":52.37403,"lon":4.88969}},{"city":"Breda","zip":"4818 CK","country":"Netherlands","geoPoint":{"lat":51.58656,"lon":4.77596}},{"city":"Eindhoven","zip":"5623 EJ","country":"Netherlands","geoPoint":{"lat":51.44083,"lon":5.47778}},{"city":"Haarlem","zip":"2035 RC","country":"Netherlands","geoPoint":{"lat":52.38084,"lon":4.63683}},{"city":"Nieuwegein","zip":"3435 CM","country":"Netherlands","geoPoint":{"lat":52.02917,"lon":5.08056}},{"city":"Rotterdam","zip":"3045 PM","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"city":"Sittard-Geleen","zip":"6162 BG","country":"Netherlands"},{"city":"The Hague","zip":"2504 LN","country":"Netherlands","geoPoint":{"lat":52.07667,"lon":4.29861}},{"city":"Zaandam","zip":"1502 DV","country":"Netherlands","geoPoint":{"lat":52.43854,"lon":4.82643}},{"city":"Balashikha","zip":"143900","country":"Russia","geoPoint":{"lat":55.79479,"lon":37.94794}},{"city":"Irkutsk","zip":"664035","country":"Russia","geoPoint":{"lat":52.29566,"lon":104.29076}},{"city":"Krasnodar","zip":"350086","country":"Russia","geoPoint":{"lat":45.04534,"lon":38.98178}},{"city":"Moscow","zip":"115478","country":"Russia","geoPoint":{"lat":55.75204,"lon":37.61781}},{"city":"Saint Petersburg","zip":"197089","country":"Russia","geoPoint":{"lat":59.93863,"lon":30.31413}},{"city":"Bundang City","zip":"463-802","country":"South Korea"},{"city":"Daegu","zip":"700-712","country":"South Korea","geoPoint":{"lat":35.87028,"lon":128.59111}},{"city":"Gyeonggi-do","zip":"410-769","country":"South Korea","geoPoint":{"lat":37.58944,"lon":126.76917}},{"city":"Seoul","zip":"110746","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"120-752","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"135-710","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"137-807","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Seoul","zip":"138-736","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"city":"Palma de Mallorca","state":"Balearic Islands","zip":"07198","country":"Spain","geoPoint":{"lat":39.56939,"lon":2.65024}},{"city":"Las Palmas de Gran Canaria","state":"Las Palmas","zip":"35016","country":"Spain","geoPoint":{"lat":28.10178,"lon":-15.41573}},{"city":"Madrid","state":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"Madrid","state":"Madrid","zip":"28041","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"Madrid","state":"Madrid","zip":"28046","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"city":"San Cristóbal de La Laguna","state":"Tenerife","zip":"38320","country":"Spain","geoPoint":{"lat":28.4853,"lon":-16.32014}},{"city":"Gävle","zip":"80187","country":"Sweden","geoPoint":{"lat":60.67452,"lon":17.14174}},{"city":"Linköping","zip":"58185","country":"Sweden","geoPoint":{"lat":58.41086,"lon":15.62157}},{"city":"Lund","zip":"22185","country":"Sweden","geoPoint":{"lat":55.70584,"lon":13.19321}},{"city":"Uppsala","zip":"751 85","country":"Sweden","geoPoint":{"lat":59.85882,"lon":17.63889}},{"city":"Zurich","zip":"8091","country":"Switzerland","geoPoint":{"lat":47.36667,"lon":8.55}},{"city":"Antalya","zip":"07070","country":"Turkey (Türkiye)","geoPoint":{"lat":36.90812,"lon":30.69556}},{"city":"Izmir","zip":"35110","country":"Turkey (Türkiye)","geoPoint":{"lat":38.41273,"lon":27.13838}},{"city":"Al Ain City","zip":"15258","country":"United Arab Emirates","geoPoint":{"lat":24.19167,"lon":55.76056}}]},"referencesModule":{"references":[{"pmid":"23835708","type":"DERIVED","citation":"Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikstrom A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol. 2013 Aug 20;31(24):3004-11. doi: 10.1200/JCO.2012.42.3749. Epub 2013 Jul 8."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Of the 376 participants enrolled in this study, 3 participants did not start induction phase treatment.","recruitmentDetails":"A total of 414 participants were screened out of which 38 participants were excluded for not meeting the eligibility criteria, declining to participate, or for other reasons. A total of 376 participants were recruited over an 18-month period across 81 centers in 11 countries from 17 August 2009 to 3 May 2011.","groups":[{"id":"FG000","title":"Induction Treatment Phase","description":"Bevacizumab 7.5 milligram (mg)/ kilogram (kg) + cisplatin 75 mg/m\\^2 + pemetrexed 500 mg/m\\^2 was administered intravenously (IV) every 3 weeks. Participants received 4 cycles of induction therapy."},{"id":"FG001","title":"Bevacizumab Maintenance Treatment (Trt) Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"FG002","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \\[mcg\\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."}],"periods":[{"title":"Induction Treatment Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"376"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"253"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"123"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"77"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Protocol Violation","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Physician Decision","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Didn't meet maintenance phase criteria","reasons":[{"groupId":"FG000","numSubjects":"27"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Other Reason","reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}]}]},{"title":"Maintenance Treatment Phase","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"125"},{"groupId":"FG002","numSubjects":"128"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"77"},{"groupId":"FG002","numSubjects":"83"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"48"},{"groupId":"FG002","numSubjects":"45"}]}],"dropWithdraws":[{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"42"},{"groupId":"FG002","numSubjects":"34"}]},{"type":"Investigators decision","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"},{"groupId":"FG002","numSubjects":"8"}]},{"type":"Other reason","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"The Intent-to-treat (ITT) population included all the participants that were randomized.","groups":[{"id":"BG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"BG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \\[mcg\\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"125"},{"groupId":"BG001","value":"128"},{"groupId":"BG002","value":"253"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"59.5","spread":"8.25"},{"groupId":"BG001","value":"59.3","spread":"8.86"},{"groupId":"BG002","value":"59.4","spread":"8.55"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"55"},{"groupId":"BG001","value":"54"},{"groupId":"BG002","value":"109"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"70"},{"groupId":"BG001","value":"74"},{"groupId":"BG002","value":"144"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Progression Free Survival During Maintenance Treatment Phase","description":"Progression free survival (PFS) is defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST v1.1) , or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Progression is defined using (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, the appearance of new lesions and increase of at least 5 mm in the sum of diameters of target lesions.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","populationDescription":"The ITT population included all the participants that were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \\[mcg\\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"128"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.6","lowerLimit":"6.0","upperLimit":"7.8"},{"groupId":"OG001","value":"10.2","lowerLimit":"9.1","upperLimit":"11.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.50","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.37","ciUpperLimit":"0.69"}]},{"type":"SECONDARY","title":"Overall Survival During Maintenance Treatment Phase","description":"Overall survival (OS) is assessed from the date of first induction treatment until the date of death. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","populationDescription":"The ITT population included all the participants that were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \\[mcg\\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"128"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.7","lowerLimit":"14.3","upperLimit":"NA","comment":"Data unavailable, as the follow-up time was very short to observe enough survival events."},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"NA","comment":"Data unavailable, as the follow-up time was very short to observe enough survival events."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.230","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.75","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.47","ciUpperLimit":"1.20"}]},{"type":"SECONDARY","title":"Best Overall Response Rate During Maintenance Treatment Phase","description":"The best overall response rate (BORR) is defined as the percentage of participants having achieved confirmed Complete Response (CR) and Partial Response (PR) as the best overall response. CR was defined as complete disappearance of all target lesions and non-target disease. PR was defined as a greater than or equal to (≥) 30% decrease under baseline of the sum of diameters of all target lesions. Stable disease (SD) is defined as steady state of disease with neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD).Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","populationDescription":"The ITT population which included all the participants that were randomized.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \\[mcg\\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"128"}]}],"classes":[{"title":"Partial response (PR)","categories":[{"measurements":[{"groupId":"OG000","value":"50","lowerLimit":"40.9","upperLimit":"59.1"},{"groupId":"OG001","value":"55.5","lowerLimit":"46.4","upperLimit":"64.3"}]}]},{"title":"Stable disease (SD)","categories":[{"measurements":[{"groupId":"OG000","value":"50","lowerLimit":"40.9","upperLimit":"59.1"},{"groupId":"OG001","value":"44.5","lowerLimit":"35.7","upperLimit":"53.6"}]}]}]},{"type":"SECONDARY","title":"Duration of Response During Maintenance Treatment Phase","description":"Duration of response is defined as the time in months from the initial start of response PR or better to the earlier of documented PD or death due to any cause. Participants who had neither progressed nor died at the date of clinical cutoff, who withdrew from the study, were lost to follow-up, or were without documented disease progression were censored at the date of the last available tumor assessment. The analysis was based on all participants with measurable disease at baseline who achieved response.Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","populationDescription":"The ITT population included all the participants that were randomized.Participants available at particular time point for assessment were included in the analysis.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \\[mcg\\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"71"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"4.9","upperLimit":"7.2"},{"groupId":"OG001","value":"9.2","lowerLimit":"6.8","upperLimit":"10.4"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.006","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.53","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.34","ciUpperLimit":"0.84"}]},{"type":"SECONDARY","title":"Duration of Disease Control During Maintenance Treatment Phase","description":"Duration of disease control is defined as the time in months from randomization to the earlier of documented PD or death due to any cause. Tumor assessment was done before Cycle 3, at Cycle 2 of maintenance therapy and every nine weeks thereafter.","populationDescription":"The ITT population included all the participants that were randomized.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Months","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 microgram \\[mcg\\] daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"128"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","lowerLimit":"3.9","upperLimit":"5.7"},{"groupId":"OG001","value":"7.8","lowerLimit":"6.8","upperLimit":"9.7"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","statisticalMethod":"Log Rank","paramType":"Hazard Ratio (HR)","paramValue":"0.52","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.38","ciUpperLimit":"0.70"}]},{"type":"SECONDARY","title":"Incidence of Adverse Events and Serious Adverse Event","description":"An adverse events (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not considered related to the medicinal (investigational) product. An serious adverse event (SAE) is any experience that suggests a significant hazard, contraindication, side effect, or precaution.","populationDescription":"The safety population comprised of all participants who received at least one dose of study medication. Participants who received induction treatment and were not randomised to maintenance treatment are also included in analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Among the 125 participants allocated to Bevacizumab Maintenance Trt Arm A, five participants did not receive treatment so they were excluded from analysis."},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Among the 128 participants allocated to Bevacizumab +Pemetrexed Maintenance Trt Arm B, three participants did not receive treatment so they were excluded from analysis."},{"id":"OG002","title":"No Maintenance Trt","description":"A total of 128 participants were not randomized to maintenance therapy because of discontinuations related to an AE, progressive disease, withdrawal of consent, or other reasons. Five participants in Bevacizumab Maintenance Trt Arm A and three in Bevacizumab +Pemetrexed Maintenance Trt Arm B, respectively, did not receive maintenance treatment so they were also included in the not randomized arm."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"128"}]}],"classes":[{"title":"AE","categories":[{"measurements":[{"groupId":"OG000","value":"116"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"119"}]}]},{"title":"SAE","categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"70"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Marked Laboratory Abnormalities","description":"Marked laboratory abnormalities were defined as those values that were outside the reference range and showed a clinically relevant change from Baseline. The reference range for Platelets was 100-550 (10\\^9/L), for White blood cells (WBC) was 3.0-18.0 (10\\^9/L), for Lymphocytes was 0.70-7.60 (10\\^9/L), and Neutrophil 1.50-9.25 (10\\^9/L ).","populationDescription":"The safety population comprised of all participants who received at least one dose of study medication. Participants who received induction treatment and were not randomised to maintenance treatment are also included in analysis.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Among the 125 participants allocated to Bevacizumab Maintenance Trt Arm A, five participants did not receive treatment so they were excluded from analysis."},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Among the 128 participants allocated to Bevacizumab +Pemetrexed Maintenance Trt Arm B, three participants did not receive treatment so they were excluded from analysis.."},{"id":"OG002","title":"No Maintenance Trt","description":"A total of 128 participants were not randomized to maintenance therapy because of discontinuations related to an AE, progressive disease, withdrawal of consent, or other reasons. Five participants in Bevacizumab Maintenance Trt Arm A and three in Bevacizumab +Pemetrexed Maintenance Trt Arm B, respectively, did not receive maintenance treatment so they were also included in the not randomized arm..."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"120"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"128"}]}],"classes":[{"title":"Alanine amino transferase (ALT)","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"8"}]}]},{"title":"Aspartate amino transferase (AST)","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"8"}]}]},{"title":"Alkaline phosphatase","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"8"}]}]},{"title":"Hemoglobin","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"25"}]}]},{"title":"International normalized ratio (INR)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]},{"title":"Lymphocytes","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"25"}]}]},{"title":"Neutrophils","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"25"}]}]},{"title":"Platelets","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"25"}]}]},{"title":"Serum creatinine","categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"8"}]}]},{"title":"WBC","categories":[{"measurements":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"30"},{"groupId":"OG002","value":"25"}]}]},{"title":"Activated partial thromboplastin time (aPTT)","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}]}]}]},{"type":"SECONDARY","title":"Quality of Life","description":"European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Cancer 30 (EORTC QLQ-C30): included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Lung Cancer 13 \\[EORTC QLQ-LC13\\]consisted of 1 multi-item scale and 9 single items that assessed the specific symptoms (dyspnea, cough, hemoptysis, and site specific pain), side effects (sore mouth, dysphagia, neuropathy, and alopecia), and pain medication use of lung cancer participants receiving chemotherapy. Scale score range: 0 to 100. Higher symptom score = greater degree of symptom severity. QOL was assessed using Pre-Induction Baseline (Pre-ind BL), Maintenance (MTC), End of study (EOS) cycles.","populationDescription":"The ITT population included all the participants that were randomized.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Score on scale","timeFrame":"Up to 21 months","groups":[{"id":"OG000","title":"Bevacizumab Maintenance Trt Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. The first cycle of maintenance therapy had to be administered a maximum of 4 weeks after the fourth cycle of induction therapy"},{"id":"OG001","title":"Bevacizumab +Pemetrexed Maintenance Trt Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500 mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Pemetrexed-treated participants received standard supplementation with folic acid orally (350 to 1000 mcg daily), vitamin B12 intramuscularly (1000 mcg every 3 cycles), and dexamethasone prophylaxis orally (4 mg twice a day) on Days -1, 1, and 2 of each cycle. The first cycle of maintenance therapy was to be administered a maximum of 4 weeks after the fourth cycle of induction therapy."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"125"},{"groupId":"OG001","value":"128"}]}],"classes":[{"title":"[Pre-ind BL] Global Health Status Scale n=116,121","categories":[{"measurements":[{"groupId":"OG000","value":"57.9","spread":"23.90"},{"groupId":"OG001","value":"59.7","spread":"21.74"}]}]},{"title":"[Pre-ind BL] Physical Functional Scale (n=118,121)","categories":[{"measurements":[{"groupId":"OG000","value":"74.8","spread":"23.69"},{"groupId":"OG001","value":"79.4","spread":"18.09"}]}]},{"title":"[Pre-ind BL] Role Functional Scale (n=118,121)","categories":[{"measurements":[{"groupId":"OG000","value":"68.4","spread":"32.50"},{"groupId":"OG001","value":"71.1","spread":"28.28"}]}]},{"title":"[Pre-ind BL] Emotional Functional Scale n=117,121","categories":[{"measurements":[{"groupId":"OG000","value":"71.7","spread":"21.93"},{"groupId":"OG001","value":"69.8","spread":"21.97"}]}]},{"title":"[Pre-ind BL] Cognitive Functional Scale n=117,121","categories":[{"measurements":[{"groupId":"OG000","value":"86.0","spread":"21.55"},{"groupId":"OG001","value":"88.0","spread":"16.70"}]}]},{"title":"[Pre-ind BL]] Social Functional Scale (n=116,120)","categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":"25.60"},{"groupId":"OG001","value":"78.7","spread":"26.10"}]}]},{"title":"[Pre-ind BL] Fatigue Symptom Scale (n=118,121)","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":"27.18"},{"groupId":"OG001","value":"31.5","spread":"21.73"}]}]},{"title":"[Pre-ind BL] Nausea & Vomiting Scale n=118,121","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"17.50"},{"groupId":"OG001","value":"4.3","spread":"12.46"}]}]},{"title":"[Pre-ind BL] Pain Symptom Scale (n=118,121)","categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":"31.92"},{"groupId":"OG001","value":"24.7","spread":"26.88"}]}]},{"title":"[Pre-ind BL] Dyspnea Symptom Scale (n=118,121)","categories":[{"measurements":[{"groupId":"OG000","value":"29.7","spread":"30.75"},{"groupId":"OG001","value":"30.6","spread":"29.69"}]}]},{"title":"[Pre-ind BL] Insomnia Symptom Scale n=118,121","categories":[{"measurements":[{"groupId":"OG000","value":"33.3","spread":"34.59"},{"groupId":"OG001","value":"33.9","spread":"30.42"}]}]},{"title":"[Pre-ind BL] Appetite Loss Symptom Scale n=118,121","categories":[{"measurements":[{"groupId":"OG000","value":"19.2","spread":"30.01"},{"groupId":"OG001","value":"18.7","spread":"29.15"}]}]},{"title":"[Pre-ind BL]] Constipation Symptom Scale n=118,121","categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":"30.68"},{"groupId":"OG001","value":"9.1","spread":"20.18"}]}]},{"title":"[Pre-ind BL] Diarrhea Symptom Scale (n=117,121)","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"17.96"},{"groupId":"OG001","value":"5.2","spread":"14.91"}]}]},{"title":"[Pre-ind BL]Financial Difficulties Scale n=114,120","categories":[{"measurements":[{"groupId":"OG000","value":"17.3","spread":"30.48"},{"groupId":"OG001","value":"17.2","spread":"29.62"}]}]},{"title":"[MTC Cycle 3]Global Health Status (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"63.3","spread":"20.02"},{"groupId":"OG001","value":"58.6","spread":"19.71"}]}]},{"title":"[MTC Cycle 3]Physical Functional Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"77.1","spread":"20.72"},{"groupId":"OG001","value":"76.0","spread":"20.37"}]}]},{"title":"[MTC Cycle 3]Role Functional Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"74.2","spread":"27.79"},{"groupId":"OG001","value":"69.9","spread":"28.51"}]}]},{"title":"[MTC Cycle 3]Emotional Functional Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"82.5","spread":"19.86"},{"groupId":"OG001","value":"78.4","spread":"18.48"}]}]},{"title":"[MTC Cycle 3]Cognitive Functional Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"84.3","spread":"23.20"},{"groupId":"OG001","value":"82.6","spread":"19.17"}]}]},{"title":"[MTC Cycle 3]Social Functional Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":"25.62"},{"groupId":"OG001","value":"73.0","spread":"24.28"}]}]},{"title":"[MTC Cycle 3]Fatigue Symptom Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"32.1","spread":"22.88"},{"groupId":"OG001","value":"34.5","spread":"21.50"}]}]},{"title":"[MTC Cycle 3]Nausea and Vomiting Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"16.78"},{"groupId":"OG001","value":"8.8","spread":"12.92"}]}]},{"title":"[MTC Cycle 3]Pain Symptom Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"23.9","spread":"27.64"},{"groupId":"OG001","value":"17.4","spread":"21.85"}]}]},{"title":"[MTC Cycle 3]Dyspnea Symptom Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":"27.93"},{"groupId":"OG001","value":"29.9","spread":"26.91"}]}]},{"title":"MTC Cycle 3]Appetite Loss Symptom Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":"22.37"},{"groupId":"OG001","value":"18.4","spread":"25.80"}]}]},{"title":"[MTC Cycle 3]Insomnia Symptom Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"19.3","spread":"24.53"},{"groupId":"OG001","value":"19.5","spread":"25.19"}]}]},{"title":"[MTC Cycle 3]Constipation Symptom Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"19.22"},{"groupId":"OG001","value":"11.1","spread":"20.12"}]}]},{"title":"[MTC Cycle 3]Diarrhea Symptom Scale (n=69,87)","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","spread":"12.97"},{"groupId":"OG001","value":"5.7","spread":"14.56"}]}]},{"title":"[MTC Cycle 3]Financial Difficulties Scale (n=68,86","categories":[{"measurements":[{"groupId":"OG000","value":"18.1","spread":"27.88"},{"groupId":"OG001","value":"19.4","spread":"26.30"}]}]},{"title":"[MTC Cycle 5] Global Health Status (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"63.2","spread":"20.36"},{"groupId":"OG001","value":"62.9","spread":"18.81"}]}]},{"title":"[MTC Cycle 5] Physical Functional Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"78.7","spread":"21.29"},{"groupId":"OG001","value":"78.4","spread":"15.45"}]}]},{"title":"[MTC Cycle 5] Role Functional Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"74.5","spread":"31.15"},{"groupId":"OG001","value":"68.8","spread":"27.08"}]}]},{"title":"[MTC Cycle 5] Emotional Functional Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"78.8","spread":"23.76"},{"groupId":"OG001","value":"78.7","spread":"20.96"}]}]},{"title":"[MTC Cycle 5] Cognitive Functional Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"81.0","spread":"26.04"},{"groupId":"OG001","value":"84.6","spread":"18.09"}]}]},{"title":"[MTC Cycle 5] Social Functional Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"85.3","spread":"22.52"},{"groupId":"OG001","value":"77.9","spread":"22.85"}]}]},{"title":"[MTC Cycle 5] Fatigue Symptom Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"32.2","spread":"23.01"},{"groupId":"OG001","value":"34.5","spread":"22.12"}]}]},{"title":"[MTC Cycle 5] Nausea and Vomiting Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"18.05"},{"groupId":"OG001","value":"10.0","spread":"20.10"}]}]},{"title":"[MTC Cycle 5] Pain Symptom Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"23.5","spread":"26.28"},{"groupId":"OG001","value":"20.1","spread":"25.27"}]}]},{"title":"[MTC Cycle 5] Dyspnea Symptom Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":"27.96"},{"groupId":"OG001","value":"35.9","spread":"30.95"}]}]},{"title":"[MTC Cycle 5] Insomnia Symptom Scale( n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"21.6","spread":"28.92"},{"groupId":"OG001","value":"22.1","spread":"27.36"}]}]},{"title":"MTC Cycle 5] Appetite Loss Symptom Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"19.43"},{"groupId":"OG001","value":"19.9","spread":"26.63"}]}]},{"title":"[MTC Cycle 5] Constipation Symptom Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"9.2","spread":"20.09"},{"groupId":"OG001","value":"17.3","spread":"29.42"}]}]},{"title":"[MTC Cycle 5] Diarrhea Symptom Scale (n=51,77)","categories":[{"measurements":[{"groupId":"OG000","value":"10.5","spread":"20.54"},{"groupId":"OG001","value":"2.6","spread":"8.99"}]}]},{"title":"[MTC Cycle 5] Financial Difficulties Scale n=50,77","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","spread":"28.76"},{"groupId":"OG001","value":"17.7","spread":"23.31"}]}]},{"title":"[MTC Cycle 7] Global Health Status Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":"21.69"},{"groupId":"OG001","value":"61.3","spread":"19.55"}]}]},{"title":"[MTC Cycle 7] Physical Functional Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":"21.49"},{"groupId":"OG001","value":"74.7","spread":"19.38"}]}]},{"title":"[MTC Cycle 7]Role Functional Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"76.8","spread":"24.97"},{"groupId":"OG001","value":"70.8","spread":"28.79"}]}]},{"title":"[MTC Cycle 7]Emotional Functional Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":"22.27"},{"groupId":"OG001","value":"77.5","spread":"18.64"}]}]},{"title":"[MTC Cycle 7]Cognitive Functional Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"77.2","spread":"27.51"},{"groupId":"OG001","value":"81.0","spread":"18.98"}]}]},{"title":"[MTC Cycle 7]Social Functional Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"82.9","spread":"24.35"},{"groupId":"OG001","value":"72.1","spread":"28.65"}]}]},{"title":"[MTC Cycle 7]Fatigue Symptom Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"32.3","spread":"22.07"},{"groupId":"OG001","value":"33.7","spread":"24.72"}]}]},{"title":"[MTC Cycle 7]Nausea & Vomiting Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"8.3","spread":"18.88"},{"groupId":"OG001","value":"9.6","spread":"16.48"}]}]},{"title":"[MTC Cycle 7]Pain Symptom Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"21.5","spread":"23.86"},{"groupId":"OG001","value":"19.8","spread":"23.55"}]}]},{"title":"[MTC Cycle 7]Dyspnea Symptom Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"28.1","spread":"26.31"},{"groupId":"OG001","value":"37","spread":"32.59"}]}]},{"title":"[MTC Cycle 7]Insomnia Symptom Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"16.7","spread":"26.57"},{"groupId":"OG001","value":"28.6","spread":"30.21"}]}]},{"title":"[MTC Cycle 7]Appetite Loss Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":"21.11"},{"groupId":"OG001","value":"21.4","spread":"29.32"}]}]},{"title":"[MTC Cycle 7]Constipation Symptom Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":"28.61"},{"groupId":"OG001","value":"17.2","spread":"24.48"}]}]},{"title":"[MTC Cycle 7]Diarrhea Symptom Scale (n=38,64)","categories":[{"measurements":[{"groupId":"OG000","value":"8.8","spread":"20.04"},{"groupId":"OG001","value":"8.9","spread":"21.61"}]}]},{"title":"[MTC Cycle 7]Financial Difficulties Scale n=38,64","categories":[{"measurements":[{"groupId":"OG000","value":"14.0","spread":"24.05"},{"groupId":"OG001","value":"20.3","spread":"27.61"}]}]},{"title":"[MTC Cycle 9 ]Global Health Status Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"60.6","spread":"18.67"},{"groupId":"OG001","value":"61.2","spread":"17.71"}]}]},{"title":"[MTC Cycle 9 ]Physical Functional Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"80.8","spread":"20.53"},{"groupId":"OG001","value":"74.9","spread":"19.54"}]}]},{"title":"[MTC Cycle 9 ]Role Functional Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"75.8","spread":"24.33"},{"groupId":"OG001","value":"69.7","spread":"28.51"}]}]},{"title":"[MTC Cycle 9 ]Emotional Functional Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"82.3","spread":"18.61"},{"groupId":"OG001","value":"75","spread":"22.46"}]}]},{"title":"[MTC Cycle 9 ]Cognitive Functional Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"83.3","spread":"20.41"},{"groupId":"OG001","value":"81.7","spread":"19.99"}]}]},{"title":"[MTC Cycle 9 ]Social Functional Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"83.8","spread":"24.47"},{"groupId":"OG001","value":"71.7","spread":"26.78"}]}]},{"title":"[MTC Cycle 9 ]Fatigue Symptom Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"28.3","spread":"24.07"},{"groupId":"OG001","value":"35.1","spread":"25.03"}]}]},{"title":"[MTC Cycle 9 ]Nausea & Vomiting Symptom (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"12.14"},{"groupId":"OG001","value":"12.0","spread":"20.77"}]}]},{"title":"[MTC Cycle 9 ]Pain Symptom Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"25.8","spread":"30.93"},{"groupId":"OG001","value":"18.7","spread":"21.47"}]}]},{"title":"[MTC Cycle 9 ]Dyspnea Symptom Scale (n=32,50)","categories":[{"measurements":[{"groupId":"OG000","value":"25.0","spread":"25.40"},{"groupId":"OG001","value":"35.3","spread":"27.28"}]}]},{"title":"[MTC Cycle 9 ]Insomnia Symptom Scale (n=33,49)","categories":[{"measurements":[{"groupId":"OG000","value":"23.2","spread":"26.98"},{"groupId":"OG001","value":"30.6","spread":"33.91"}]}]},{"title":"[MTC Cycle 9 ]Appetite Loss Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"10.1","spread":"19.52"},{"groupId":"OG001","value":"23.3","spread":"29.55"}]}]},{"title":"[MTC Cycle 9 ]Constipation Symptom Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"13.1","spread":"24.92"},{"groupId":"OG001","value":"16.0","spread":"25.41"}]}]},{"title":"[MTC Cycle 9 ]Diarrhea Symptom Scale (n=33,50)","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":"20"},{"groupId":"OG001","value":"7.3","spread":"18.18"}]}]},{"title":"[MTC Cycle 9]Financial Difficulties Scale n=33,50","categories":[{"measurements":[{"groupId":"OG000","value":"15.2","spread":"23.70"},{"groupId":"OG001","value":"22.0","spread":"27.45"}]}]},{"title":"[MTC Cycle 11 ] Global Health Status Scale n=25,37","categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":"18.93"},{"groupId":"OG001","value":"59.9","spread":"21.41"}]}]},{"title":"[MTC Cycle 11 ]Physical Functional Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"79.2","spread":"16.48"},{"groupId":"OG001","value":"81.1","spread":"17.81"}]}]},{"title":"[MTC Cycle 11 ]Role Functional Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"77.3","spread":"18.56"},{"groupId":"OG001","value":"73.9","spread":"27.37"}]}]},{"title":"[MTC Cycle 11 ]Emotional Functional Scale n=25,37","categories":[{"measurements":[{"groupId":"OG000","value":"78.3","spread":"19.09"},{"groupId":"OG001","value":"80.0","spread":"19.88"}]}]},{"title":"[MTC Cycle 11 ]Cognitive Functional Scale n=25,37","categories":[{"measurements":[{"groupId":"OG000","value":"81.3","spread":"26.49"},{"groupId":"OG001","value":"84.2","spread":"17.10"}]}]},{"title":"[MTC Cycle 11 ]Social Functional Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"84.7","spread":"19.20"},{"groupId":"OG001","value":"77.9","spread":"27.51"}]}]},{"title":"[MTC Cycle 11 ]Fatigue Symptom Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"32.4","spread":"22.20"},{"groupId":"OG001","value":"31.2","spread":"20.92"}]}]},{"title":"[MTC Cycle 11 ]Nausea & Vomiting Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"15.96"},{"groupId":"OG001","value":"9.5","spread":"18.23"}]}]},{"title":"[MTC Cycle 11 ]Pain Symptom Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"29.3","spread":"28.98"},{"groupId":"OG001","value":"19.8","spread":"27.45"}]}]},{"title":"[MTC Cycle 11 ]Dyspnea Symptom Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"30.7","spread":"16.44"},{"groupId":"OG001","value":"28.8","spread":"27.40"}]}]},{"title":"[MTC Cycle 11 ]Insomnia Symptom Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"20.0","spread":"23.57"},{"groupId":"OG001","value":"18.9","spread":"26.69"}]}]},{"title":"[MTC Cycle 11 ]Appetite Loss Scale (n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"9.3","spread":"20.46"},{"groupId":"OG001","value":"18","spread":"26.75"}]}]},{"title":"MTC Cycle 11 ]Constipation Symptom Scale( n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"6.7","spread":"13.61"},{"groupId":"OG001","value":"17.1","spread":"24.37"}]}]},{"title":"[MTC Cycle 11 ]Diarrhea Symptom Scale ( n=25,37)","categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"6.67"},{"groupId":"OG001","value":"7.2","spread":"15.98"}]}]},{"title":"[MTC Cycle 11]Financial Difficulties Scale n=24,37","categories":[{"measurements":[{"groupId":"OG000","value":"15.3","spread":"25.97"},{"groupId":"OG001","value":"18.0","spread":"26.75"}]}]},{"title":"[EOS]Global Health Status Scale (n=123,127)","categories":[{"measurements":[{"groupId":"OG000","value":"55.1","spread":"20.62"},{"groupId":"OG001","value":"57.2","spread":"20.01"}]}]},{"title":"[EOS]Physical Functional Scale (n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"70.2","spread":"23.49"},{"groupId":"OG001","value":"72.5","spread":"22.06"}]}]},{"title":"[EOS]Role Functional Scale (n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"63.5","spread":"32.43"},{"groupId":"OG001","value":"64.3","spread":"29.68"}]}]},{"title":"[EOS]Emotional Functional Scale (n=124,127)","categories":[{"measurements":[{"groupId":"OG000","value":"74.4","spread":"21.36"},{"groupId":"OG001","value":"77.3","spread":"20.20"}]}]},{"title":"[EOS]Cognitive Functional Scale ( n=124,127)","categories":[{"measurements":[{"groupId":"OG000","value":"79.3","spread":"24.91"},{"groupId":"OG001","value":"83.5","spread":"19.30"}]}]},{"title":"[EOS]Social Functional Scale (n=124,127)","categories":[{"measurements":[{"groupId":"OG000","value":"73.3","spread":"29.28"},{"groupId":"OG001","value":"72.6","spread":"27.90"}]}]},{"title":"[EOS]Fatigue Symptom Scale (n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"41.0","spread":"26.42"},{"groupId":"OG001","value":"37.6","spread":"23.80"}]}]},{"title":"[EOS]Nausea & Vomiting Scale (n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"14.4","spread":"23.70"},{"groupId":"OG001","value":"12.3","spread":"20.70"}]}]},{"title":"[EOS]Pain Symptom Scale (n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"30.4","spread":"30.31"},{"groupId":"OG001","value":"21.1","spread":"25.58"}]}]},{"title":"[EOS]Dyspnea Symptom Scale (n=124,127)","categories":[{"measurements":[{"groupId":"OG000","value":"31.5","spread":"29.85"},{"groupId":"OG001","value":"34.1","spread":"29.83"}]}]},{"title":"[EOS]Insomnia Symptom Scale( n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"27.2","spread":"26.57"},{"groupId":"OG001","value":"22.6","spread":"28.45"}]}]},{"title":"[EOS]Appetite Loss Symptom Scale (n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"26.9","spread":"31.31"},{"groupId":"OG001","value":"26.0","spread":"30.26"}]}]},{"title":"[EOS]Constipation Symptom Scale (n=125,127)","categories":[{"measurements":[{"groupId":"OG000","value":"17.6","spread":"25.60"},{"groupId":"OG001","value":"12.1","spread":"21.28"}]}]},{"title":"[EOS]Diarrhea Symptom Scale(n=124,127)","categories":[{"measurements":[{"groupId":"OG000","value":"9.7","spread":"20.72"},{"groupId":"OG001","value":"6.8","spread":"15.34"}]}]},{"title":"[EOS]Financial Difficulties Scale (n=123,126)","categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"27.45"},{"groupId":"OG001","value":"16.9","spread":"27.24"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Up to 21 months (throughout the study)","description":"Serious adverse events and non-serious adverse events are reported in Safety Analysis Set, which consists of all participants who received at least one dose of study medication and had a safety assessment performed post baseline.","eventGroups":[{"id":"EG000","title":"No Maintenance Treatment","description":"A total of 128 participants were not randomized to maintenance therapy because of discontinuations related to an AE, progressive disease, withdrawal of consent, or other reasons. Five participants in Bevacizumab Maintenance Trt Arm A and three in Bevacizumab +Pemetrexed Maintenance Trt Arm B, respectively, did not receive maintenance treatment so they were also included in the not randomized arm..","seriousNumAffected":70,"seriousNumAtRisk":128,"otherNumAffected":105,"otherNumAtRisk":128},{"id":"EG001","title":"Maintenance Treatment Arm A","description":"Bevacizumab 7.5 mg/kg was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Among the 125 participants allocated to Bevacizumab Maintenance Trt Arm A, five participants did not receive treatment so they were excluded from analysis","seriousNumAffected":26,"seriousNumAtRisk":120,"otherNumAffected":115,"otherNumAtRisk":120},{"id":"EG002","title":"Maintenance Treatment Arm B","description":"Bevacizumab 7.5 mg/kg + pemetrexed 500mg/m\\^2 was administered IV every 3 weeks until progression of disease, unacceptable toxicity, or withdrawal of consent. Among the 128 participants allocated to Bevacizumab +Pemetrexed Maintenance Trt Arm B, three participants did not receive treatment so they were excluded from analysis..","seriousNumAffected":42,"seriousNumAtRisk":125,"otherNumAffected":120,"otherNumAtRisk":125}],"seriousEvents":[{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Anal abscess","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Device related infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Abscess limb","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Clostridial infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Gastroenteritis norovirus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Intervertebral discitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Lung infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Oesophageal candidiasis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Post procedural infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Pulmonary sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Scrub typhus","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Pulmonary embolism","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":128},{"groupId":"EG001","numAffected":3,"numAtRisk":120},{"groupId":"EG002","numAffected":2,"numAtRisk":125}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Haemoptysis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":2,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Pneumothorax","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Bronchopleural fistula","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":2,"numAtRisk":120},{"groupId":"EG002","numAffected":2,"numAtRisk":125}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":2,"numAtRisk":120},{"groupId":"EG002","numAffected":3,"numAtRisk":125}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":2,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Gastric haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Gastrointestinal toxicity","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Intestinal ischaemia","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Oesophageal perforation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Pancreatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Rectal haemorrhage","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Tongue oedema","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"General physical health deterioration","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Sudden death","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Haemorrhagic cyst","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Hyperthermia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Impaired healing","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Febrile neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Pancytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Febrile bone marrow aplasia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":2,"numAtRisk":125}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":2,"numAtRisk":125}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Hypercalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Hypercreatininaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Hypocalcaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":2,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Thrombophlebitis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Embolism arterial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Embolism venous","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Iliac artery embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Peripheral arterial occlusive disease","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Thrombophlebitis superficial","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Vasculitis necrotising","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Transient ischaemic attack","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":2,"numAtRisk":125}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Posterior reversible encephalopathy syndrome","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Presyncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Viith nerve paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":2,"numAtRisk":125}]},{"term":"Renal failure acute","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Cardiac asthma","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Cardiogenic shock","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Cardiomyopathy","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Pericardial effusion","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"General physical condition abnormal","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Muscle spasms","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Cholelithiasis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Hepatic vein thrombosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Hepatotoxicity","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Portal vein thrombosis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Femoral neck fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Respiratory fume inhalation disorder","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Confusional state","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]},{"term":"Psychotic disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Vitreous detachment","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":1,"numAtRisk":125}]},{"term":"Dermal cyst","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":0,"numAtRisk":125}]}],"otherEvents":[{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":47,"numAtRisk":128},{"groupId":"EG001","numAffected":73,"numAtRisk":120},{"groupId":"EG002","numAffected":77,"numAtRisk":125}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":128},{"groupId":"EG001","numAffected":28,"numAtRisk":120},{"groupId":"EG002","numAffected":33,"numAtRisk":125}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":128},{"groupId":"EG001","numAffected":33,"numAtRisk":120},{"groupId":"EG002","numAffected":32,"numAtRisk":125}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":128},{"groupId":"EG001","numAffected":16,"numAtRisk":120},{"groupId":"EG002","numAffected":35,"numAtRisk":125}]},{"term":"Abdominal pain upper","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":128},{"groupId":"EG001","numAffected":8,"numAtRisk":120},{"groupId":"EG002","numAffected":11,"numAtRisk":125}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":5,"numAtRisk":120},{"groupId":"EG002","numAffected":8,"numAtRisk":125}]},{"term":"Stomatitis","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":8,"numAtRisk":125}]},{"term":"Dry mouth","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":1,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Asthenia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":25,"numAtRisk":128},{"groupId":"EG001","numAffected":42,"numAtRisk":120},{"groupId":"EG002","numAffected":31,"numAtRisk":125}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":128},{"groupId":"EG001","numAffected":22,"numAtRisk":120},{"groupId":"EG002","numAffected":40,"numAtRisk":125}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":128},{"groupId":"EG001","numAffected":15,"numAtRisk":120},{"groupId":"EG002","numAffected":15,"numAtRisk":125}]},{"term":"Mucosal inflammation","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":128},{"groupId":"EG001","numAffected":7,"numAtRisk":120},{"groupId":"EG002","numAffected":15,"numAtRisk":125}]},{"term":"Oedema peripheral","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":128},{"groupId":"EG001","numAffected":4,"numAtRisk":120},{"groupId":"EG002","numAffected":19,"numAtRisk":125}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":16,"numAtRisk":125}]},{"term":"Cough","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":128},{"groupId":"EG001","numAffected":27,"numAtRisk":120},{"groupId":"EG002","numAffected":27,"numAtRisk":125}]},{"term":"Epistaxis","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":128},{"groupId":"EG001","numAffected":26,"numAtRisk":120},{"groupId":"EG002","numAffected":24,"numAtRisk":125}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":128},{"groupId":"EG001","numAffected":21,"numAtRisk":120},{"groupId":"EG002","numAffected":26,"numAtRisk":125}]},{"term":"Dysphonia","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":128},{"groupId":"EG001","numAffected":7,"numAtRisk":120},{"groupId":"EG002","numAffected":8,"numAtRisk":125}]},{"term":"Dyspnoea exertional","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":4,"numAtRisk":125}]},{"term":"Rhinorrhoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":3,"numAtRisk":120},{"groupId":"EG002","numAffected":9,"numAtRisk":125}]},{"term":"Neutropenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":128},{"groupId":"EG001","numAffected":26,"numAtRisk":120},{"groupId":"EG002","numAffected":26,"numAtRisk":125}]},{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":17,"numAtRisk":128},{"groupId":"EG001","numAffected":20,"numAtRisk":120},{"groupId":"EG002","numAffected":21,"numAtRisk":125}]},{"term":"Thrombocytopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":8,"numAtRisk":120},{"groupId":"EG002","numAffected":3,"numAtRisk":125}]},{"term":"Leukopenia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":8,"numAtRisk":125}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":128},{"groupId":"EG001","numAffected":43,"numAtRisk":120},{"groupId":"EG002","numAffected":55,"numAtRisk":125}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":128},{"groupId":"EG001","numAffected":19,"numAtRisk":120},{"groupId":"EG002","numAffected":26,"numAtRisk":125}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":128},{"groupId":"EG001","numAffected":7,"numAtRisk":120},{"groupId":"EG002","numAffected":11,"numAtRisk":125}]},{"term":"Paraesthesia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":4,"numAtRisk":120},{"groupId":"EG002","numAffected":11,"numAtRisk":125}]},{"term":"Dysgeusia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Peripheral sensory neuropathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":128},{"groupId":"EG001","numAffected":3,"numAtRisk":120},{"groupId":"EG002","numAffected":9,"numAtRisk":125}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":128},{"groupId":"EG001","numAffected":11,"numAtRisk":120},{"groupId":"EG002","numAffected":13,"numAtRisk":125}]},{"term":"Musculoskeletal pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":14,"numAtRisk":120},{"groupId":"EG002","numAffected":11,"numAtRisk":125}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":11,"numAtRisk":120},{"groupId":"EG002","numAffected":11,"numAtRisk":125}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":5,"numAtRisk":120},{"groupId":"EG002","numAffected":11,"numAtRisk":125}]},{"term":"Bone pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":11,"numAtRisk":120},{"groupId":"EG002","numAffected":2,"numAtRisk":125}]},{"term":"Decreased appetite","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":24,"numAtRisk":128},{"groupId":"EG001","numAffected":23,"numAtRisk":120},{"groupId":"EG002","numAffected":32,"numAtRisk":125}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":128},{"groupId":"EG001","numAffected":2,"numAtRisk":120},{"groupId":"EG002","numAffected":8,"numAtRisk":125}]},{"term":"Weight decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":16,"numAtRisk":128},{"groupId":"EG001","numAffected":7,"numAtRisk":120},{"groupId":"EG002","numAffected":8,"numAtRisk":125}]},{"term":"Blood creatinine increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":11,"numAtRisk":125}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":128},{"groupId":"EG001","numAffected":0,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":3,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Nasopharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":8,"numAtRisk":120},{"groupId":"EG002","numAffected":19,"numAtRisk":125}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":128},{"groupId":"EG001","numAffected":8,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":128},{"groupId":"EG001","numAffected":3,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Alopecia","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":8,"numAtRisk":128},{"groupId":"EG001","numAffected":11,"numAtRisk":120},{"groupId":"EG002","numAffected":20,"numAtRisk":125}]},{"term":"Rash","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":8,"numAtRisk":120},{"groupId":"EG002","numAffected":10,"numAtRisk":125}]},{"term":"Renal impairment","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":7,"numAtRisk":125}]},{"term":"Lacrimation increased","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":3,"numAtRisk":120},{"groupId":"EG002","numAffected":16,"numAtRisk":125}]},{"term":"Conjunctivitis","organSystem":"Eye disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":5,"numAtRisk":125}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":9,"numAtRisk":120},{"groupId":"EG002","numAffected":9,"numAtRisk":125}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 14.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":128},{"groupId":"EG001","numAffected":6,"numAtRisk":120},{"groupId":"EG002","numAffected":9,"numAtRisk":125}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights."},"pointOfContact":{"title":"Roche Trial Information Hotline","organization":"F. Hoffmann-La Roche AG","email":"global.trial_information@roche.com","phone":"+41 616878333"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2025-12-17","removedCountries":["Kuwait","Portugal"]},"interventionBrowseModule":{"meshes":[{"id":"D000068258","term":"Bevacizumab"},{"id":"D002945","term":"Cisplatin"},{"id":"D000068437","term":"Pemetrexed"}],"ancestors":[{"id":"D061067","term":"Antibodies, Monoclonal, Humanized"},{"id":"D000911","term":"Antibodies, Monoclonal"},{"id":"D000906","term":"Antibodies"},{"id":"D007136","term":"Immunoglobulins"},{"id":"D007162","term":"Immunoproteins"},{"id":"D001798","term":"Blood Proteins"},{"id":"D011506","term":"Proteins"},{"id":"D000602","term":"Amino Acids, Peptides, and Proteins"},{"id":"D012712","term":"Serum Globulins"},{"id":"D005916","term":"Globulins"},{"id":"D017606","term":"Chlorine Compounds"},{"id":"D007287","term":"Inorganic Chemicals"},{"id":"D017672","term":"Nitrogen Compounds"},{"id":"D017671","term":"Platinum Compounds"},{"id":"D006147","term":"Guanine"},{"id":"D007042","term":"Hypoxanthines"},{"id":"D011688","term":"Purinones"},{"id":"D011687","term":"Purines"},{"id":"D006574","term":"Heterocyclic Compounds, 2-Ring"},{"id":"D000072471","term":"Heterocyclic Compounds, Fused-Ring"},{"id":"D006571","term":"Heterocyclic Compounds"},{"id":"D005971","term":"Glutamates"},{"id":"D024342","term":"Amino Acids, Acidic"},{"id":"D000596","term":"Amino Acids"},{"id":"D000600","term":"Amino Acids, Dicarboxylic"}]}},"hasResults":true}